The Dong-A University College of Medicine study found participants in the highest 20% of hemoglobin levels had a 7% higher risk of all-cause dementia and an 18% higher risk of vascular dementia.

Overview Debates Related claims Topics Sources

Machine-learning models integrating early antibody signatures discriminated individuals who would later develop Crohn's disease or ulcerative colitis from healthy controls up to 10 years before diagnosis, with AUC values of 0.90 and 0.84, respectively.

Early Alzheimer's symptoms such as hearing impairment can reduce engagement in physical activity, triggering accelerated cognitive and memory decline.

A UK study of 1,139 people over age 50 found that moderate to vigorous physical activity reduced dementia risk by 34% to 50% over eight to ten years.

Study co-author Dr. You Zhou stated that combining gut bacteria and digestive chemicals distinguished individuals with mild cognitive impairment from healthy people with high accuracy.

Researchers from Cardiff University and Imperial College London found that older adults with mild cognitive impairment displayed significantly elevated levels of Izemoplasmatales spp. bacteria and the chemical proline in fecal samples.

The study utilized machine learning algorithms to analyze fecal sample biomarkers to diagnose mild cognitive impairment and predict condition progression speed.

Researchers profiled antibody responses against approximately 357,000 antigens across 2,000 serum samples, identifying 123,980 unique antibodies and finding significantly lower antibody diversity in individuals who later developed Crohn's disease or ulcerative colitis.

Brain health benefits against Alzheimer's tau protein accumulation appeared at 3,000 steps daily, with an optimal protective plateau between 5,000 and 7,500 steps daily.

A study tracking almost 300 older adults found that physical activity did not reduce toxic amyloid plaques, but reduced signs of dementia by almost half in more active participants.

In older adults with early brain signs of Alzheimer's, physical activity reduced the accumulation of misfolded tau proteins in specific brain areas over nine to 11 years, according to a study tracking participants with pedometers.

A 2022 UK study tracking 78,430 people for seven years using wrist accelerometers found a 25% reduction in dementia risk at 3,800 daily steps, rising to 50% at 9,800 steps.

Cardiovascular and stroke risk factors including elevated cholesterol, poor sleep, high blood pressure, and diabetes increase dementia risk alongside physical inactivity.

Dr. Aasma Shaukat stated at the ACG Annual Scientific Meeting that researchers plan to develop future iterations beyond version two of SimpleScreen CRC to further increase sensitivity for advanced lesions.

Dr. Aasma Shaukat and her research team plan to submit the updated SimpleScreen CRC test to the FDA for regulatory approval.

In an ongoing Phase 1/2a trial in healthy volunteers, Arrowhead Pharmaceuticals' experimental RNA interference therapeutic ARO-MAPT administered via subcutaneous injection reduced cerebrospinal fluid total tau protein by an average of 73% at day 105 in the highest dose cohort receiving 12.8 mg/kg on days 1 and 15, with maximum individual reduction reaching 85%.

The Phase 1/2a trial of ARO-MAPT aims to enroll 112 total participants, expanding from healthy volunteers into patients with early Alzheimer's disease receiving up to five subcutaneous injections, with further data updates expected in 2027.

Arrowhead Pharmaceuticals reported that ARO-MAPT was generally well tolerated in healthy volunteers, with no serious adverse events, deaths, or toxicity-related study dropouts, and mild reported side effects including injection site reactions, vessel puncture bruising, respiratory infections, and headaches.

Healthy volunteers receiving subcutaneous ARO-MAPT doses of 2.1 mg/kg and 6.4 mg/kg on days 1, 8, and 15 in the Phase 1/2a trial achieved average cerebrospinal fluid tau reductions of 40% and 69% respectively at day 105.

ARO-MAPT is designed to silence expression of the microtubule-associated protein tau (MAPT) gene in the central nervous system, targeting pathological tau protein aggregation implicated in Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy.

Arrowhead Pharmaceuticals is in discussions with health regulators to initiate clinical trials evaluating ARO-MAPT in patients with MAPT-associated frontotemporal dementia and progressive supranuclear palsy.